Core Insights - Gelteq Limited has received FDA approval for a suitability petition for a new animal drug under development, utilizing its ingestible gel platform for nutrient and drug delivery [1][2] - The approval allows Gelteq to expedite its entry into the animal pharmaceuticals market by proposing a change from pill form to oral gel form, which does not require further safety and effectiveness studies [2] - Gelteq aims to address challenges in traditional drug delivery methods, such as difficulty swallowing and taste issues, across various sectors including pharmaceuticals, nutraceuticals, and animal medications [3] Company Overview - Gelteq Limited is a clinical and biotechnology company headquartered in Melbourne, Australia, focusing on white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and sports nutrition [3] - The company is advancing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition [3] - Gelteq's unique formulation aims to improve medication delivery efficiency and user experience, addressing common issues associated with traditional methods [3]

Core Viewpoint - Gelteq Limited is entering production of 400,000 units of its gel solution, aimed at fulfilling orders in the U.S. and Australia, with expected delivery in January 2025 [1][2] Company Overview - Gelteq Limited is a clinical and science-based company headquartered in Melbourne, Australia, focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products [3] - The company targets five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition [3] Production and Sales - The current production run includes Gelteq nutraceutical products in sports, anti-aging, and weight loss categories [1] - The production run is seen as a validation of Gelteq's gel-based technology and its ability to generate revenues in the near term [2] Partnerships and Growth - Gelteq has strengthened its partnership with Monash Innovation Labs to effectively scale operations and meet client needs while ensuring product quality [2] - The substantial orders related to the current production run are expected to lead to even larger volume orders in the future [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _____________. OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 O ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations.   Gelteq Co-Founder and CEO Nathan Givoni stated, “The appointment of ...